# To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

> **NCT00120328** · PHASE3 · TERMINATED · sponsor: **Speedel Pharma Ltd.** · enrollment: 2364 (—)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** SPP301

## Key facts

- **NCT ID:** NCT00120328
- **Lead sponsor:** Speedel Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 2364 (—)
- **Last updated:** 2007-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120328, "To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00120328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*